Results of three clinical trials, published in the New England Journal of Medicine, support percutaneous closure of patent foramen ovale (PFO) to prevent recurrent stroke after a cryptogenic stroke, which could lead to a change in the professional guidelines on the treatment of these patients and help the companies trying to market PFO-closure devices.
On Sept. 14, The New England Journal of Medicine published long-term results of three clinical trials comparing PFO-closure with a transcatheter device and medical therapy to medical therapy alone: RESPECT,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?